LLY vs DGX
By Alex · Tickerpine
Eli Lilly and Company vs Quest Diagnostics Incorporated, side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | DGX |
|---|---|---|
| Price | $1,273.46 | $241.89 |
| Market cap | $1.14T | $26.70B |
| P/E ratio | 42.7 | 24.1 |
| ROE | 102.29% | 15.32% |
| Profit margin | 33.53% | 9.54% |
| Revenue growth | 47.70% | 10.00% |
| Dividend yield | 0.54% | 1.42% |
| Beta | 0.45 | — |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs DGX in plain English
- LLY is the bigger company — about 42.5× the market cap of DGX.
- DGX is cheaper on earnings (P/E 24.1 vs 42.7).
- LLY earns a higher return on equity (102% vs 15%).
- LLY is growing revenue faster (48% vs 10%).
- DGX has the higher dividend yield (1.42% vs 0.54%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
DGX return calculator
See what $1,000 in Quest Diagnostics Incorporated would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.